# EDGAR Filing Document

**Accession Number:** 0001426800
**File Stem:** 0001193125-26-116132
**Filing Date:** 2026-3
**Character Count:** 27405
**Document Hash:** 2d2a4168c273be15d8b2e6cf76de3f67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-116132.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001193125-26-116132

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**EFFECTIVENESS DATE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASSEMBLY BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001426800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294449
- **FILM NUMBER:** 26774961

**BUSINESS ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (833) 409-4583

**MAIL ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VENTRUS BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20080211

**As filed with the Securities and Exchange Commission on March 19, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Assembly Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **20-8729264** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **Two Tower Place, 7<sup>th</sup> Floor<br>South San Francisco, California** | **94080** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan** 

**(Full title of the plan)** 

**Jason A. Okazaki** 

**Chief Executive Officer and President** 

**Assembly Biosciences, Inc.** 

**Two Tower Place, 7<sup>th</sup> Floor** 

**South San Francisco, California 94080** 

**(Name and address of agent for service)** 

**(833) 509-4583** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**P. Michelle Gasaway, Esq.** 

**Skadden, Arps, Slate, Meagher & Flom LLP** 

**300 South Grand Avenue, Suite 3400** 

**Los Angeles, California 90071** 

**(213) 687-5000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Pursuant to General Instruction E to Form S-8 under the Securities Act, this Registration Statement is being filed by Assembly Biosciences, Inc. (the "<u>Company</u>" or the "<u>Registrant</u>") for the purpose of registering additional shares of the Company's Common Stock under the Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan (the "<u>2014 Plan</u>").

Under the terms of the 2014 Plan, shares of Common Stock underlying awards granted under the Company's 2010 Equity Incentive Plan, upon being repurchased by the Company or forfeited on or after June 2, 2016, will become issuable under the 2014 Plan. This Registration Statement registers the 19,863 shares of Common Stock under the 2010 Equity Incentive Plan that are issuable under the 2014 Plan.

**Prior Registration Statements** 

The 19,863 additional shares of Common Stock available for issuance under the 2014 Plan registered pursuant to this Registration Statement are of the same class of securities as the shares of Common Stock registered for issuance under the 2014 Plan pursuant to the following currently effective registration statements: (1) the Registration Statement on Form S-8 (Registration No. 333-198803) filed on September 17, 2014 (the "<u>Original 2014 Plan Registration Statement</u>"); (2) the Registration Statement on Form S-8 (Registration No. 333-213019) filed on August 9, 2016 (the "<u>Second 2014 Plan Registration Statement</u>"); (3) the Registration Statement on Form S-8 (Registration No. 333-234580) filed on November 7, 2019 (the "<u>Third 2014 Plan Registration Statement</u>"); and the Registration Statement on Form S-8 (Registration No. 333-273836) filed on August 9, 2023 (the "<u>Fourth 2014 Plan Registration Statement</u>"). The contents of the Original 2014 Plan Registration Statement, the Second 2014 Plan Registration Statement, the Third 2014 Plan Registration Statement and the Fourth, including any amendments thereto or filings incorporated therein, are incorporated herein by reference. Any items in the Original 2014 Plan Registration Statement, the Second 2014 Plan Registration Statement, the Third 2014 Plan Registration Statement and the Fourth 2014 Plan Registration Statement not expressly changed by this Registration Statement shall be as set forth in the 2014 Plan Registration Statement, the Second 2014 Plan Registration Statement, the Third 2014 Plan Registration Statement and the Fourth 2014 Plan Registration Statement, as applicable.

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The documents containing the information specified in Part I will be delivered in accordance with Form S-8 and Rule 428(b) under the Securities Act. Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the "<u>Commission</u>"), either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The following documents, which have been filed with the Commission by the Company pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act"</u>), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company's [Annual Report on Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001426800/000119312526115992/asmb-20251231.htm) for the year ended December 31, 2025, filed with the Commission on March 19, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the information specifically incorporated by reference in the Company's Form 10-K from the Company's [Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001426800/000095017025057353/asmb-20250422.htm) , filed with the Commission on April 23, 2025); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the description of the Company's common stock in the Company's Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1426800/000114420410065909/v205146_8a12b.htm) (File No. 001-35005) filed with the Commission on December 10, 2010, including any amendment or report filed by the Company for the purpose of
updating such description, including [Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024](http://www.sec.gov/Archives/edgar/data/1426800/000095017024038057/asmb-ex4_2.htm) , filed with the Commission on March 22, 2023.

All documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of common stock registered hereunder have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Item 2.02 or 7.01 or any related Item 9.01 of Form 8-K that is not deemed filed under such provisions.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

You may request a copy of these filings, at no cost, by writing or telephoning the Company at:

Two Tower Place, 7<sup>th</sup> Floor

South San Francisco, California 94080

Telephone: (833) 509-4583

Attn: Corporate Secretary

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Company has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

**Item 4.** **Description of Securities.** <br>

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.** <br>

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.** <br>

Not applicable.

------

**Item 7.** **Exemption from Registration Claimed.** <br>

Not applicable.

**Item 8.** **Exhibits.** <br>

See the Exhibit Index on the page immediately preceding the signatures to this Registration Statement for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

**Item 9.** **Undertakings.** <br>

Not required to be filed with this Registration Statement pursuant to General Instruction E to Form S-8.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 4.1 | [Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 3.1 of the Registrant's Annual Report on Form 10-K filed with the Commission on March 28, 2024).](http://www.sec.gov/Archives/edgar/data/1426800/000095017024038057/asmb-ex3_1.htm) |
| 4.2 | [Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc., dated February 9, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on February 13, 2024.](http://www.sec.gov/Archives/edgar/data/1426800/000095017024014534/asmb-ex3_1.htm) |
| 4.3 | [Amended and Restated Bylaws of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on December 13, 2024.](http://www.sec.gov/Archives/edgar/data/1426800/000095017024136183/asmb-ex3_1.htm) |
| 4.3 | [Specimen Common Stock Certificate of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 4.1 of the Registrant's Annual Report on Form 10-K filed with the Commission on March 20, 2025).](http://www.sec.gov/Archives/edgar/data/1426800/000095017025042673/asmb-ex4_1.htm) |
| 5.1 | [Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.](d83979dex51.htm) |
| 23.1 | [Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).](d83979dex51.htm) |
| 23.2 | [Consent of Independent Registered Public Accounting Firm.](d83979dex232.htm) |
| 24.1 | [Power of Attorney (included on the signature page of this Registration Statement).](#sig) |
| 99.1 | [Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on June 6, 2016.](http://www.sec.gov/Archives/edgar/data/1426800/000114420416107050/v441808_ex10-1.htm) |
| 107 | [Filing Fees.](d83979dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on March 19, 2026.

---

| | |
|:---|:---|
| **Assembly Biosciences, Inc.** | **Assembly Biosciences, Inc.** |
| By: | /s/ Jason A. Okazaki |
|  | Jason A. Okazaki |
|  | Chief Executive Officer and President |

---

------

**POWER OF ATTORNEY** 

We, the undersigned officers and directors of Assembly Biosciences, Inc., hereby severally constitute and appoint Jason A. Okazaki and John O. Gunderson, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him/her and in his/her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons on March 19, 2026 in the capacities indicated.

---

| | |
|:---|:---|
| **Signature** | **Title** |
| /s/ Jason A. Okazaki | Director, Chief Executive Officer and President<br> (Principal Executive Officer) |
| Jason A. Okazaki | Director, Chief Executive Officer and President<br> (Principal Executive Officer) |
| /s/ Jeanette M. Bjorkquist | VP, Finance<br> (Principal Financial Officer and Principal Accounting Officer) |
| Jeanette M. Bjorkquist | VP, Finance<br> (Principal Financial Officer and Principal Accounting Officer) |
| /s/ William R. Ringo, Jr. | Chairman of the Board |
| William R. Ringo, Jr. |  |
| /s/ Anthony E. Altig | Director |
| Anthony E. Altig |  |
| /s/ Tomas Cihlar, Ph.D. | Director |
| Tomas Cihlar |  |
| /s/ Gina Consylman | Director |
| Gina Consylman |  |
| /s/ Robert D. Cook II | Director |
| Robert D. Cook II |  |
| /s/ Michael Houghton, Ph.D. | Director |
| Michael Houghton, Ph.D. |  |
| /s/ Lisa R. Johnson-Pratt, M.D. | Director |
| Lisa R. Johnson-Pratt, M.D. |  |
| /s/ Susan Mahony, Ph.D. | Director |
| Susan Mahony, Ph.D. |  |
| /s/ John G. McHutchison, A.O., M.D. | Director |
| John G. McHutchison, A.O., M.D. |  |

---

## Exhibit 5.1

**Exhibit 5.1** 

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

2000 AVENUE OF THE STARS

---

| | |
|:---|:---|
| LOS ANGELES, CALIFORNIA 90067-4732<br> ___________<br>TEL: (213) 687-5000<br> FAX: (213) 687-5600<br> www.skadden.com<br>March 19, 2026 | FIRM/AFFILIATE<br> OFFICES<br> ——————<br> BOSTON<br> CHICAGO<br> HOUSTON<br> NEW YORK<br> PALO ALTO<br> WASHINGTON, D.C.<br> WILMINGTON<br> ——————<br> ABU DHABI<br> BEIJING<br> BRUSSELS<br> FRANKFURT<br> HONG KONG<br> LONDON<br> MOSCOW<br> MUNICH<br> PARIS<br> SÃO PAULO<br> SEOUL<br> SINGAPORE<br> TOKYO<br> TORONTO |

---

Assembly Biosciences, Inc.

Two Tower Place, 7th Floor

South San Francisco, California 94080

Re: Assembly Biosciences, Inc.

<u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as special United States counsel to Assembly Biosciences, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with its filing with the Securities and Exchange Commission (the "<u>Commission</u>") of a registration statement on Form S-8 (the "<u>Registration Statement</u>") under the Securities Act of 1933 (the "<u>Securities Act</u>") on the date hereof, relating to the registration by the Company of an aggregate of 19,863 shares (the "<u>2014 Plan Shares</u>") of common stock of the Company, par value $0.001 per share (the "<u>Common Stock</u>") for issuance pursuant to the Assembly Biosciences, Inc. 2014 Stock Incentive Plan, effective as of September 17, 2014 (the "<u>2014 Original Plan</u>"), as amended and restated by the Amended and Restated 2014 Stock Incentive Plan, effective as of June 2, 2016 (the "<u>Amended and Restated 2014 Plan</u>"), and as further amended by the Omnibus Amendment to the 2014 Plan, effective as of March 11, 2020 (the "<u>Omnibus Amendment</u>" and, collectively with the 2014 Original Plan and the Amended and Restated 2014 Plan, the "<u>2014 Plan</u>").

This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

In rendering the opinions stated herein, we have examined and relied upon the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registration Statement;

------

Assembly Biosciences, Inc.

March 19, 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an executed copy of a certificate, dated the date hereof, of John Gunderson, Vice President, General Counsel and Corporate Secretary of the Company (the "<u>Secretary's Certificate</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) copies of the Company's (i) Third Amended and Restated Certificate of Incorporation, as amended, (ii) Fourth Amended and Restated Certificate of Incorporation, and (iii) Sixth Amended and Restated Certificate of Incorporation, as amended, certified by the Secretary of State of the State of Delaware as of March 18, 2026 (the "<u>Current Charter</u>"), and, in each case, certified pursuant to the Secretary's Certificate as being in effect on the date of the respective resolutions referred to below and, in the case of the Current Charter, as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a copy of the Company's (i) Amended and Restated Bylaws, (ii) Amended and Restated Bylaws, as amended, and (iii) Amended and Restated Bylaws (the "<u>Current Bylaws</u>") and, in each case, certified pursuant to the Secretary's Certificate as being in effect on the date of the respective resolutions referred to below and, in the case of the Current Bylaws, as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) copies of certain resolutions of the Board of Directors of the Company, certified pursuant to the Secretary's Certificate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) copies of the 2014 Original Plan, the Amended and Restated 2014 Plan and the Omnibus Amendment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) the forms of award agreements under the 2014 Plan.

We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates and receipts of public officials, certificates of officers or other representatives of the Company and others, and such other documents as we have deemed necessary or appropriate as a basis for the opinions set forth herein.

In our examination, we have assumed the genuineness of all signatures, including electronic signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic, certified or photocopied copies, and the authenticity of the originals of such copies. As to any facts relevant to the opinions stated herein that we did not independently establish or verify, we have relied upon statements and representations of officers and other representatives of the Company and others and of public officials, including the facts and conclusions set forth in the Secretary's Certificate and the Current Charter.

------

Assembly Biosciences, Inc.

March 19, 2026

In rendering the opinions stated herein, we have also assumed that: (i) an appropriate account statement evidencing the 2014 Plan Shares credited to a recipient's account maintained with the Company's transfer agent has been or will be issued by the Company's transfer agent, (ii) the issuance of the 2014 Plan Shares has been properly recorded in the books and records of the Company, (iii) each award agreement pursuant to which rights to acquire 2014 Plan Shares or other awards are granted pursuant to the 2014 Plan will be consistent with the 2014 Plan and will be duly authorized, executed and delivered by the parties thereto, (iv) the consideration received by the Company for each of the 2014 Plan Shares delivered pursuant to the 2014 Plan shall not be less than the per share par value of the 2014 Plan Shares, (v) the Company's issuance of the 2014 Plan Shares does not and will not (a) except to the extent expressly stated in the opinions contained herein, violate any statute to which the Company or such issuance is subject, or (b) constitute a violation of, or a breach under, or require the consent or approval of any other person under, any agreement or instrument binding on the Company (except that we do not make this assumption with respect to the Current Charter and the Current Bylaws although we have assumed compliance with any covenant, restriction or provision with respect to financial ratios or tests or any aspect of the financial condition or results of operations of the Company contained in such instruments) and that the Company will continue to have sufficient authorized shares of Common Stock, and (vi) the Company's authorized capital stock is as set forth in the Current Charter and we have relied solely on the certified copy thereof issued by the Secretary of State of the State of Delaware and have not made any other inquiries or investigations.

We do not express any opinion with respect to the laws of any jurisdiction other than the General Corporation Law of the State of Delaware (the "<u>DGCL</u>").

Based upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that the 2014 Plan Shares have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and, when issued, delivered and paid for in accordance with the terms of the 2014 Plan and the respective award agreement, the 2014 Plan Shares will be validly issued, fully paid and nonassessable.

------

Assembly Biosciences, Inc.

March 19, 2026

We hereby consent to the filing of this opinion letter with the Commission as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. This opinion letter is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.

---

| |
|:---|
| Very truly yours, |
| /s/ Skadden, Arps, Slate, Meagher & Flom LLP |

---

## Exhibit 23.2

**Exhibit 23.2** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated 2014 Stock Incentive Plan of Assembly Biosciences, Inc. of our report dated March 19, 2026, with respect to the consolidated financial statements of Assembly Biosciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Jose, California

March 19, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**ASSEMBLY BIOSCIENCES, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share | Other | 19863 | $28.42 | $564506.46 | 0.0001381 | $77.96 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $564506.46  |  | $77.96  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $77.96  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Represents 19,863 additional shares of Common Stock reserved for issuance under the Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act) , this registration statement shall also cover any additional shares of the registrant's securities that become issuable by reason of any share splits, share dividends or similar transactions. (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price is calculated pursuant to Rule 457(c) and Rule 457(h) under the Securities Act based on the average of the high and low sale prices of the Registrant's common stock as reported by The Nasdaq Global Select Market on March 13, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---